Howard M. Sandler focuses on Radiation therapy, Prostate cancer, Prostate, Surgery and Internal medicine. His Radiation therapy research includes elements of Salvage therapy, Proportional hazards model, Nuclear medicine and Urology. His biological study spans a wide range of topics, including Gynecology and Brachytherapy.
He combines subjects such as Pelvis, Dose fractionation, Rectum, Toxicity and Adenocarcinoma with his study of Prostate. Howard M. Sandler interconnects Relative risk and Radiology in the investigation of issues within Surgery. His research on Internal medicine frequently connects to adjacent areas such as Oncology.
His main research concerns Prostate cancer, Radiation therapy, Internal medicine, Oncology and Prostate. While the research belongs to areas of Prostate cancer, Howard M. Sandler spends his time largely on the problem of Urology, intersecting his research to questions surrounding Toxicity. His work carried out in the field of Radiation therapy brings together such families of science as Hormonal therapy, Proportional hazards model and Nuclear medicine.
Much of his study explores Internal medicine relationship to Gynecology. His research investigates the connection between Oncology and topics such as Chemotherapy that intersect with problems in Bladder cancer. His work deals with themes such as Rectum, Univariate analysis and Adenocarcinoma, which intersect with Prostate.
His primary areas of investigation include Prostate cancer, Internal medicine, Oncology, Radiation therapy and Randomized controlled trial. His study in Prostate cancer is interdisciplinary in nature, drawing from both Stage, Prostate and Clinical trial. The Oncology study combines topics in areas such as Evidence based guideline, Phases of clinical research, Meta-analysis, Hazard ratio and Prostate-specific antigen.
Within one scientific family, Howard M. Sandler focuses on topics pertaining to Prospective cohort study under Radiation therapy, and may sometimes address concerns connected to Brachytherapy. The study incorporates disciplines such as Disease and Salvage radiotherapy in addition to Randomized controlled trial. As part of one scientific family, Howard M. Sandler deals mainly with the area of Prostatectomy, narrowing it down to issues related to the Surgery, and often Radiology.
Howard M. Sandler spends much of his time researching Prostate cancer, Internal medicine, Oncology, Radiation therapy and Randomized controlled trial. His Prostate cancer research is multidisciplinary, incorporating elements of Stage, Guideline and Prostate. His Prostate study integrates concerns from other disciplines, such as External beam radiotherapy and Urology.
His Internal medicine research incorporates themes from Heredity and Gynecology. His Oncology research is multidisciplinary, relying on both Phases of clinical research, Hazard ratio, Biochemical recurrence, Prospective cohort study and Genetic testing. Radiation therapy is a subfield of Surgery that Howard M. Sandler tackles.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach;Gerald Hanks;Howard Thames;Paul Schellhammer.
International Journal of Radiation Oncology Biology Physics (2006)
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda;Rodney L. Dunn;Jeff Michalski;Howard M. Sandler.
The New England Journal of Medicine (2008)
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
John T Wei;Rodney L Dunn;Rodney L Dunn;Mark S Litwin;Howard M Sandler.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Andrew J. Stephenson;Peter T. Scardino;Michael W. Kattan;Thomas M. Pisansky.
Journal of Clinical Oncology (2007)
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
Gerald E. Hanks;Thomas F. Pajak;Arthur Porter;David Grignon.
Journal of Clinical Oncology (2003)
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
Eric M. Horwitz;Kyounghwa Bae;Gerald E. Hanks;Arthur Porter.
Journal of Clinical Oncology (2008)
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Christopher U. Jones;Daniel Hunt;David G. McGowan;Mahul B. Amin.
The New England Journal of Medicine (2011)
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options
Martin G. Sanda;Jeffrey A. Cadeddu;Erin Kirkby;Ronald C. Chen.
The Journal of Urology (2018)
Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
William U. Shipley;Howard D. Thames;Howard M. Sandler;Gerald E. Hanks.
Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
John T. Wei;Rodney L. Dunn;Howard M. Sandler;P. William McLaughlin.
Journal of Clinical Oncology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: